BAX icon

Baxter International

30.81 USD
+0.19
0.62%
At close Feb 10, 4:00 PM EST
After hours
30.81
+0.00
0.00%
1 day
0.62%
5 days
-2.22%
1 month
4.72%
3 months
-9.96%
6 months
-16.57%
Year to date
5.30%
1 year
-23.57%
5 years
-66.25%
10 years
-56.13%
 

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Employees: 60,000

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

26% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 94

17% more call options, than puts

Call options by funds: $141M | Put options by funds: $121M

14% more funds holding in top 10

Funds holding in top 10: 7 [Q2] → 8 (+1) [Q3]

13% more capital invested

Capital invested by funds: $15.7B [Q2] → $17.7B (+$2.02B) [Q3]

2% more funds holding

Funds holding: 862 [Q2] → 875 (+13) [Q3]

0.33% less ownership

Funds ownership: 91.85% [Q2] → 91.52% (-0.33%) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 299 | Existing positions reduced: 310

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$35
14%
upside
Avg. target
$37
18%
upside
High target
$38
23%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Citigroup
Joanne Wuensch
65% 1-year accuracy
30 / 46 met price target
14%upside
$35
Neutral
Maintained
11 Dec 2024
Stifel
Rick Wise
69% 1-year accuracy
24 / 35 met price target
23%upside
$38
Buy
Maintained
11 Nov 2024

Financial journalist opinion

Based on 7 articles about BAX published over the past 30 days

Neutral
Zacks Investment Research
14 hours ago
Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Evaluate the expected performance of Baxter (BAX) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Negative
Market Watch
1 week ago
20 stocks leading the stock-market plunge on Monday as Trump brings down the tariff hammer
Among the S&P 500, 91% of stocks showed early declines following President Trump's announcements of tariffs against Canada, Mexico and China.
20 stocks leading the stock-market plunge on Monday as Trump brings down the tariff hammer
Neutral
Reuters
1 week ago
Baxter CEO José Almeida to retire after near decade-long tenure
Medical products maker Baxter International said on Monday its CEO José Almeida will retire effective immediately, after nearly a decade as the company's top boss.
Baxter CEO José Almeida to retire after near decade-long tenure
Neutral
Business Wire
1 week ago
Baxter Announces CEO Retirement and Appointment of COO
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025. The Baxter Board of Directors has appointed lead independent director Brent Shafer as chair and interim CEO and has initiated a search for a permanent CEO with the ass.
Baxter Announces CEO Retirement and Appointment of COO
Negative
Zacks Investment Research
2 weeks ago
New Strong Sell Stocks for January 27th
BASFY, BNPQY and BAX have been added to the Zacks Rank #5 (Strong Sell) List on January 27, 2024.
New Strong Sell Stocks for January 27th
Neutral
Business Wire
2 weeks ago
Baxter to Host Fourth-Quarter 2024 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.
Baxter to Host Fourth-Quarter 2024 Financial Results Conference Call for Investors
Negative
Zacks Investment Research
2 weeks ago
Bear of the Day: Baxter (BAX)
In the world of equities, not all stocks shine brightly in the heavens. Some inevitably find themselves in the shadows, struggling against the tides of market sentiment.
Bear of the Day: Baxter (BAX)
Neutral
Business Wire
1 month ago
Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Saturday, July 12, 2025. About Baxter Every day, millions of.
Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference
Positive
Zacks Investment Research
1 month ago
Baxter Stock May Gain Following Five New Injectable Product Launches
BAX launches five new injectible products in the United States, thus further strengthening its U.S Pharmaceuticals business segment.
Baxter Stock May Gain Following Five New Injectable Product Launches
Neutral
Business Wire
2 months ago
Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, today announced five new injectable pharmaceutical product launches in the U.S., joining the previous five launches announced in April of this year and marking a total of 10 U.S. injectable product launches in 2024. “Our Pharmaceuticals teams are relentlessly focused on bringing differentiated products to market that support our customers in helping to address.
Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S.
Charts implemented using Lightweight Charts™